Hsbc Holdings PLC Makes New $2.59 Million Investment in Exelixis, Inc. $EXEL

Hsbc Holdings PLC purchased a new position in Exelixis, Inc. (NASDAQ:EXEL) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 47,538 shares of the biotechnology company’s stock, valued at approximately $2,594,000.

Several other hedge funds also recently modified their holdings of EXEL. Motiv8 Investments LLC purchased a new position in shares of Exelixis during the fourth quarter valued at approximately $26,000. Cassaday & Co Wealth Management LLC purchased a new stake in Exelixis in the 1st quarter worth approximately $27,000. Acumen Wealth Advisors LLC purchased a new stake in Exelixis in the 4th quarter worth approximately $29,000. Western Wealth Management LLC acquired a new position in Exelixis in the 1st quarter valued at $29,000. Finally, Northwestern Mutual Wealth Management Co. raised its holdings in Exelixis by 1,380.4% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 773 shares during the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis News Roundup

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Strong sales and earnings, along with reported institutional support, have helped Exelixis shares gain 43.5% over the past year. The company’s latest reported quarter also showed adjusted earnings of $0.91 per share, ahead of the $0.85 consensus estimate, while revenue increased 10.6% year over year. Strong Sales, Earnings Send Exelixis Shares Higher
• Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $3.18 from $3.12 and increased its Q1 2027 estimate to $0.80 from $0.79. It also lifted its Q3 2027 forecast slightly to $0.93 from $0.92, suggesting some confidence in near-term earnings execution.
• Neutral Sentiment: Exelixis remains near its 52-week high, with shares recently trading around $54.45 versus a high of $57.57. Its valuation is approximately 17 times earnings, while the company continues to show strong profitability, including a reported 35.3% net margin and 42.2% return on equity.
• Negative Sentiment: Zacks Research maintains a “Strong Sell” rating and made several downward revisions: FY2027 EPS fell to $3.57 from $3.60, Q2 2027 EPS declined to $0.84 from $0.89, Q4 2026 EPS decreased to $0.81 from $0.83, and Q1 2028 EPS edged down to $0.96 from $0.97. These cuts could pressure the stock despite the modest upward revisions elsewhere.
• Negative Sentiment: Options activity was unusually bearish on August 27, with traders purchasing 10,010 put contracts—about 826% above the average daily put volume of 1,081. The surge indicates increased demand for downside protection or speculation on a decline.

Exelixis Price Performance

NASDAQ EXEL opened at $54.45 on Monday. The firm has a market capitalization of $13.49 billion, a P/E ratio of 17.12, a P/E/G ratio of 1.62 and a beta of 0.44. Exelixis, Inc. has a 1-year low of $33.76 and a 1-year high of $57.57. The business’s 50-day simple moving average is $54.57 and its 200-day simple moving average is $49.04.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.06. Exelixis had a return on equity of 42.17% and a net margin of 35.33%.The business had revenue of $628.69 million during the quarter, compared to analysts’ expectations of $636.40 million. During the same quarter in the previous year, the business earned $0.75 EPS. The company’s revenue for the quarter was up 10.6% on a year-over-year basis. On average, equities research analysts expect that Exelixis, Inc. will post 3.19 EPS for the current fiscal year.

Insider Transactions at Exelixis

In other news, Director Mary C. Beckerle sold 9,812 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $53.66, for a total value of $526,511.92. Following the completion of the sale, the director owned 16,079 shares of the company’s stock, valued at $862,799.14. This represents a 37.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.60% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on EXEL shares. Weiss Ratings upgraded Exelixis from a “buy (b)” rating to a “buy (a-)” rating in a report on Tuesday, August 11th. Citizens Jmp increased their target price on Exelixis from $50.00 to $55.00 and gave the stock a “market outperform” rating in a research report on Wednesday, June 24th. Wall Street Zen lowered Exelixis from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. BMO Capital Markets initiated coverage on Exelixis in a report on Tuesday, August 18th. They issued a “market perform” rating and a $54.00 price target for the company. Finally, TD Cowen upped their price objective on shares of Exelixis from $51.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $50.07.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.